Evidence map›Paper›PMID 35373402›Full record

ReviewCell proliferation2022

Tripartite motif family proteins in inflammatory bowel disease: Mechanisms and potential for interventions.

Rirong Chen, Yizhe Tie, Jinyu Lu, Li Li, Zhirong Zeng, Minhu Chen, Shenghong Zhang

Open access · goldAbstract readReview
In one paragraph

Review in Cell proliferation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rirong ChenDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Yizhe TieDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Jinyu LuDepartment of Clinical Medicine, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
Li LiDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Zhirong ZengDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Minhu ChenDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Shenghong ZhangDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID https://orcid.org/0000-0002-9088-8781
Sun Yat-sen University · CN

Funding

Guangdong Science and Technology Department 2021A1515220107Guangzhou Science and Technology Department 202002030041National Natural Science Foundation of China 81870374;82070538
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic recurrent gastrointestinal inflammatory disease that poses a heavy burden to the global healthcare system. However, the current paucity of mechanistic understanding of IBD pathogenesis hampers the development of aetiology-directed therapies. Novel therapeutic options based on IBD pathogenesis are urgently needed for attaining better long-term prognosis for IBD patients. The tripartite motif (TRIM) family is a large protein family including more than 70 structurally conservative members, typically characterized by their RBCC structure, which primarily function as E3 ubiquitin ligases in post-translational modification. They have emerged as regulators of a broad range of cellular mechanisms, including proliferation, differentiation, transcription and immune regulation. TRIM family proteins are involved in multiple diseases, such as viral infection, cancer and autoimmune disorders, including inflammatory bowel disease. This review provides a comprehensive perspective on TRIM proteins' involvement in the pathophysiology and progression of IBD, in particular, on intestinal mucosal barriers, gene susceptibility and opportunistic infections, thus providing novel therapeutic targets for this complicated disease. However, the exact mechanisms of TRIM proteins in IBD pathogenesis and IBD-related carcinogenesis are still unknown, and more studies are warranted to explore potential therapeutic targets of TRIM proteins in IBD.

Indexed as

Inflammatory Bowel DiseasesNeoplasmsHumansProtein Processing, Post-TranslationalTripartite Motif ProteinsUbiquitin-Protein LigasesTripartite Motif ProteinsUbiquitin-Protein Ligases

Identifiers

PMID35373402
PMCPMC9136508
OpenAlexW4225856545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.